Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

(2010) Dominique Descamps et al.   Human vaccines & immunotherapeutics

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Mechanism of action of clinically approved adjuvants

(2009) Bart N Lambrecht et al.   CURRENT OPINION IN IMMUNOLOGY

Follicular Helper T Cells: Lineage and Location

(2009) Nicolas Fazilleau et al.   IMMUNITY

AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity

(2009) A. M. Didierlaurent et al.   JOURNAL OF IMMUNOLOGY

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

(2009)   LANCET

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding

(2009) Nicolas Fazilleau et al.   NATURE IMMUNOLOGY

Mechanism of action of licensed vaccine adjuvants

(2009) Elaine Tritto et al.   VACCINE

Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant

(2008) C. R. Casella et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

(2008) David Jenkins   GYNECOLOGIC ONCOLOGY

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature

(2008) Tino F. Schwarz et al.   GYNECOLOGIC ONCOLOGY

Vaccine Adjuvants Alter TCR-Based Selection Thresholds

(2008) Laurent Malherbe et al.   IMMUNITY

Inflammatory signals in dendritic cell activation and the induction of adaptive immunity

(2008) Olivier Joffre et al.   IMMUNOLOGICAL REVIEWS

Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

(2008) Mirjam Kool et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

(2008) Stephanie C. Eisenbarth et al.   NATURE

New horizons in adjuvants for vaccine development

(2008) Steven G. Reed et al.   TRENDS IN IMMUNOLOGY

Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia

(2008) F. Xavier Bosch et al.   VACCINE

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

(2008) Thomas Verstraeten et al.   VACCINE

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years

(2008) Tino F. Schwarz et al.   VACCINE

Antigen presentation by monocytes and monocyte-derived cells

(2007) Gwendalyn J Randolph et al.   CURRENT OPINION IN IMMUNOLOGY